Mutation Profile of Acute Myeloid Leukaemia in a Chinese Cohort by Targeted Next-generation Sequencing

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2021 Oct 7

PMID 34617422

Citations 1

Authors

Benny Man Wai Lit

Belinda B Guo

Jacques A J Malherbe

Yok Lam Kwong

Wendy N Erber

Affiliations

Soon will be listed here.

Abstract

Background: Acute myeloid leukaemia (AML) results from the clonal expansion of blast cells of myeloid origin driven by genomic defects. The advances in next-generation sequencing (NGS) have allowed the identification of many mutated genes important in the pathogenesis of AML.

Aims: In this study, we aimed to assess the mutation types and frequency in a Chinese cohort presenting with de novo AML cohort using a targeted NGS strategy.

Methods: In total, we studied samples from 87 adult patients with de novo AML who had no prior history of cytotoxic chemotherapy. Samples were evaluated using a 120-gene targeted NGS panel to assess the mutation profile.

Results: Of the 87 AML patients, there were 60 (69%) with a normal karyotype. 89.7% of patients had variants, with an average of 1.9 mutations per patient (range: 0-5 mutations per patient). DNMT3A variants were the most common, being detected in 33 patients (37.9%). NPM1 (34.5%), IDH1/2 (24.1%) and FLT3-ITD (20.7%) mutations was the next most common. Of the patients with DNMT3A mutations, 24.2% also had mutations NPM1 and FLT3-ITD and 6.1% NPM1, FLT3-ITD and IDH mutations.

Conclusion: Both DNMT3A and NPM1 mutations were more common than in other Chinese and Western AML cohorts that have been studied. DNMT3A mutations tended to co-occur with NPM1 and FLT3-ITD mutations and were most commonly seen with a normal karyotype.

Citing Articles

Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing.

Lit B, Guo B, Malherbe J, Kwong Y, Erber W Cancer Rep (Hoboken). 2021; 5(10):e1573.

PMID: 34617422 PMC: 9575498. DOI: 10.1002/cnr2.1573.

References

Im A, Sehgal A, Carroll M, Smith B, Tefferi A, Johnson D . DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014; 28(9):1774-83. PMC: 4234093. DOI: 10.1038/leu.2014.124. View

Challen G, Sun D, Jeong M, Luo M, Jelinek J, Berg J . Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011; 44(1):23-31. PMC: 3637952. DOI: 10.1038/ng.1009. View

Welch J, Ley T, Link D, Miller C, Larson D, Koboldt D . The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2):264-78. PMC: 3407563. DOI: 10.1016/j.cell.2012.06.023. View

Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-33. PMC: 3201818. DOI: 10.1056/NEJMoa1005143. View

Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89. PMC: 3545649. DOI: 10.1056/NEJMoa1112304. View

Han X, Li W, He N, Feng P, Pang Y, Ji C . Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis. Clin Chim Acta. 2018; 479:25-37. DOI: 10.1016/j.cca.2018.01.006. View

Shlush L, Zandi S, Mitchell A, Chen W, Brandwein J, Gupta V . Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506(7488):328-33. PMC: 4991939. DOI: 10.1038/nature13038. View

Singh R, Patel K, Routbort M, Reddy N, Barkoh B, Handal B . Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15(5):607-22. DOI: 10.1016/j.jmoldx.2013.05.003. View

Kumar D, Mehta A, Panigrahi M, Nath S, Saikia K . DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. Hematol Oncol Stem Cell Ther. 2017; 11(2):82-89. DOI: 10.1016/j.hemonc.2017.09.004. View

10.

Suzuki R, Onizuka M, Kojima M, Shimada M, Okamura K, Fukagawa S . Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. Int J Hematol. 2008; 86(5):422-8. DOI: 10.1007/BF02984000. View

11.

Zhang X, Shi J, Zhang J, Yang X, Zhang G, Yang S . Clinical and biological implications of in acute myeloid leukemia with . Cancer Manag Res. 2018; 10:2457-2466. PMC: 6084071. DOI: 10.2147/CMAR.S157632. View

12.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

13.

Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M . Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29(21):2889-96. DOI: 10.1200/JCO.2011.35.4894. View

14.

Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. PMC: 2818760. DOI: 10.1038/nature08617. View

15.

Estey E . Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013; 88(4):318-27. DOI: 10.1002/ajh.23404. View

16.

Link D . Molecular genetics of AML. Best Pract Res Clin Haematol. 2012; 25(4):409-14. PMC: 3513694. DOI: 10.1016/j.beha.2012.10.002. View

17.

Meyer S, Levine R . Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014; 15(9):e382-94. DOI: 10.1016/S1470-2045(14)70008-7. View

18.

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View

19.

Tan M, Ng I, Chen Z, Ban K, Ng C, Chiu L . Clinical implications of mutations in a Southeast Asian cohort of acute myeloid leukaemia patients. J Clin Pathol. 2017; 70(8):669-676. DOI: 10.1136/jclinpath-2016-204195. View

20.

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View